NICE is unable to make a recommendation about the use in the NHS of avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours. This is because Blueprint Medicines will not be launching the technology in the UK and has confirmed it will withdraw its submission.


If NHS organisations wish to consider avapritinib for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-3946-6

  • National Institute for Health and Care Excellence (NICE)